AI Article Synopsis
- Semaglutide, a medication used for managing type 2 diabetes and obesity, has become popular but may be linked to acute pancreatitis, a serious condition.
- A case study describes a 36-year-old woman who developed sudden stomach pain after starting semaglutide for weight loss without medical advice, leading to a diagnosis of acute pancreatitis.
- After stopping semaglutide, her symptoms improved significantly, highlighting the need for greater awareness among patients and healthcare providers about the potential risks associated with this medication.
Article Abstract
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has gained recent popularity in its effective management of type 2 diabetes mellitus (T2DM) and obesity. Minimal evidence has reported the link between Semaglutide use and acute pancreatitis. In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis. Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice. Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms, making semaglutide the likely causative factor for her acute pancreatitis. Given the increased use of GLP-1RA, we aim to increase awareness among patients taking this medication whether prescribed or not and increase clinician awareness when prescribing this medication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416045 | PMC |
| http://dx.doi.org/10.7759/cureus.69844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!